Table 1.
Key characteristics of the development sample.
| Characteristic | Non-Survivors (n = 310) | Survivors (n = 200) | p-Value |
|---|---|---|---|
| Mean age (range) * | 67 (27–98) | 49 (18–90) | <0.00001 |
| Male | 192 (61.9) | 91 (45.5) | - |
| Female | 118 (38) | 109 (51.9) | - |
| Malignancy | 24 (7.7) | 0 (0.0) | 0.00005 |
| Lung disease | 57 (18.3) | 7 (3.5) | <0.00001 |
| Hypertension | 113 (36.4) | 57 (28.5) | 0.063 |
| Diabetes | 106 (34.2) | 37 (18.5) | 0.0001 |
| Heart disease | 121 (39) | 20 (10.0) | <0.00001 |
| Kidney disease | 52 (16.8) | 6 (3.0) | <0.00001 |
| Liver disease | 40 (12.9) | 4 (2.0) | 0.00002 |
| Obesity | 45 (14.5) | 13 (6.5) | 0.005 |
| Autoimmune disease | 13 (4.2) | 5 (2.5) | 0.312 |
| Recent surgery | 13 (4.2) | 1 (0.5) | 0.013 |
| Neurologic disorders | 53 (17) | 5 (2.5) | <0.00001 |
| Stroke | 27 (8.7) | 3 (1.5) | 0.001 |
| Hematological disturbances | 19 (6.1) | 0 (0.0) | 0.0003 |
* Values are n (%) unless indicated differently.